Amgen SAFE-BioPharma

maumal

Super Member
Registrato
22/9/08
Messaggi
2.596
Punti reazioni
57
:cool: SAFE-BioPharma Receives Safe Harbor Certification
Tue Oct 27, 2009 12:51pm EDT

FT. LEE, N.J.--(Business Wire)--
SAFE-BioPharma Association has certified compliance with the US Department of
Commerce and European Union Safe Harbor requirements for the protection of
personal data. The non-profit association developed and manages the global
SAFE-BioPharma digital identity and signature standard, used within the
biopharmaceutical and healthcare industries.

To qualify, SAFE-BioPharma developed its privacy policy to comply with the
E.U.`s Safe Harbor Principles. Safe Harbor Certification will enable
SAFE-BioPharma to transfer personal data outside the E.U., expediting the flow
of information between European clients and the United States. The certification
recognizes that SAFE-BioPharma`s privacy and data security policies provide
"adequate protection" for personal data from its European clients as required by
the European Union's Data Protection Directive.

"Receiving Safe Harbor status assures SAFE-BioPharma member companies that use
of the standard to manage digital identities and/or to apply digital signatures
is consistent with E.U. regulations regarding data transfer and will further
enhance our capabilities to better serve our European clients," said Mollie
Shields-Uehling, President and CEO, SAFE-BioPharma Association.

Details regarding E.U. Safe Harbor Principles are available at
http://www.safe-biopharma.org/infocenter/SafeHarborOverview.pdf.

About SAFE-BioPharma Association (www.safe-biopharma.org) SAFE-BioPharma
Association is the non-profit association that created and manages the
SAFE-BioPharma digital identity and signature standard for the pharmaceutical
and healthcare industries.

The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and
other business risk associated with business-to-business and
business-to-regulator electronic transactions. It facilitates interoperability
by providing a secure, enforceable, and regulatory-compliant way to verify
identities of parties involved in electronic transactions. Because the standard
is linked to the Federal Bridge PKI Architecture through the 4BF
(http://www.the4bf.com), a SAFE-BioPharma digital identity can be trusted by any
Federal agency. SAFE-BioPharma`s vision is to be a catalyst in transforming the
biopharmaceutical and healthcare communities to a fully electronic business
environment by 2012.

The Association`s members include:

* Abbott (NYSE:ABT)
* Amgen (NASDAQ:AMGN)
* AstraZeneca (NYSE:AZN)
* Bristol-Myers Squibb (NYSE:BMY)
* GlaxoSmithKline (NYSE:GSK)
* Johnson & Johnson (NYSE:JNJ)
* Eli Lilly (NYSE:LLY)
* McDougall Scientific
* Merck (NYSE:MRK)
* National Notary Association
* Novartis
* Pfizer (NYSE:PFE)
* Premier Inc.
* Roche
* Sanofi-Aventis (NYSE:SNY).
* ScheringPlough-Organon (NYSE:SGP)
* SNAP Diagnostics

SAFE-BioPharma is a trademark of SAFE-BioPharma Association. Any use of this
trademark requires approval from SAFE-BioPharma Association.

SAFE-BioPharma Association
Jon Weisberg
M 801-860-9977
O 801-359-9977
Jon.weisberg@safe-biopharma.org
 
Non trovo il tread che sicuramente ne parla... (nonostante la ricerca mi dia sempre tred poi aprendoli e passando pagina per pagina... nemmeno l'ombra :no:) Comunque chi la segue cosa ne pensa?
 

Allegati

  • Immagine.JPG
    Immagine.JPG
    64,8 KB · Visite: 107
mi autorispondo... almeno torno in prima pagina :rolleyes:
 
ocio...:eek:

Posted on 10/27/09 at 2:34pm

According CNBC.com, their analysts looked at Analyst Price Targets for S&P500 companies in September and identified the top 20 companies. Among these companies, 6 of the top 10 are already showing promising results. On that list, Micron Technology (NYSE: MU) has the widest price range of $4.00 to $18.00 a share making them the number three company in the top 15.

Some of these companies have already popped showing massive gains. Among those companies, Salli Mae (NYSE: SLM) and Moody’s (NYSE: MCO) has over 20% gains from the start of the Month.

The rest of the companies in the list are yet to pop include Metro PCS Communications (NYSE: PCS), Sprint Nextel (NYSE: S), Cephalon Inc. (NASDAQ: CEPH), Genworth Financial Inc. (NYSE: GNW), Marshall & Ilsly Corp. (NYSE: MI), Comcast Corp. (NASDAQ: CMCSA), Well Point Inc. (NYSE: WLP) , Game Stop Corp. (NYSE: GME) , MEMC Electronic Materials (NYSE: WFR) , State Street Corp. (NYSE: STT) , Novell Inc. (NASDAQ: NOVL) , Pactive Corp. (NYSE: PTV), and Amgen Inc. (NASDAQ: AMGN)
 
Grafico con bollinger 20gg 2%
non male mi pare...
 

Allegati

  • Immagine.JPG
    Immagine.JPG
    45,3 KB · Visite: 91
tanto per.....
un po' di didattica (tanto ci sono solo io e quindi non vado OT) :rolleyes:

Bollinger Band

A livello operativo, quotazioni che si muovono lambendo la banda superiore (upper band) indicano una buona forza del trend rialzista. Viceversa quotazioni che si muovono in prossimità della "lower band" indicano una grande debolezza del titolo.
Prezzi che si muovono al di fuori delle bande indicano notevole forza del trend in atto. Quando i prezzi sono in prossimità di una delle bande, è probabile che l'obiettivo prezzo si proietti verso la banda opposta.
Spesso, dopo un periodo di bassa volatilità (nel quale le bande si avvicinano) è possibile assistere ad un' aumento della volatilità stessa (nel quale le bande si allontanano) con un violento movimento verso l'alto o verso il basso in quanto bande molto strette spesso coincidono con fasi di accumulazione o distribuzione.
Frequentemente gli operatori associano lo studio delle Bollinger Band all'analisi di alcuni oscillatori come l'Rsi: in tal caso l'analisi abbinata delle informazioni, con particolare riferimento alle divergenze dell'oscillatore, spesso fornisce validi segnali operativi.
 
aaah... dmenticavo! Siamo sul supporto...
 
...
 
Ultima modifica:
+4.% :rolleyes:

Amgen Announces Overall Survival Results for Vectibix in First-Line Metastatic Colorectal Cancer

Phase 3 Results Reinforce Importance of KRAS Status

THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. Earlier this year, it was announced that the trial met its primary endpoint by significantly prolonging progression-free survival (PFS) in the first-line treatment of patients with KRAS wild-type mCRC.
http://www.pharmalive.com/News/index.cfm?articleid=664606
 
Indietro